These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31879152)

  • 1. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
    Bakeer M; Zubair AC; Roy V
    Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
    Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
    J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA; Linenberger M; Connelly-Smith L
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Avigan ZM; Arinsburg S; Pan D; Mark T; Fausel C; Bubalo J; Milkovich G; Moshier E; Fu W; Chari A; Richter J
    Bone Marrow Transplant; 2024 Oct; 59(10):1440-1448. PubMed ID: 39085373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
    Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
    Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ; Alexander ET; Hogan KR; Schaub C; Fouts TV; Stuart RK
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
    Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
    Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
    [No Abstract]   [Full Text] [Related]  

  • 14. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
    Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
    Guan FS; He DH; Li Y; Zhang Y; Zheng GF; Zhu YY; He JS; Zhang EF; Cai Z; Zhao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1056-1060. PubMed ID: 37551477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.